Gain Therapeutics, Inc. filings document a clinical-stage biotechnology issuer with Nasdaq-listed common stock and emerging growth company status. Recent Form 8-K disclosures cover financial results, business updates, Regulation FD materials, scientific presentations, and clinical or biomarker updates related to GT-02287 and Parkinson’s disease.
The company’s proxy materials describe annual meeting matters, director elections, board composition, executive compensation, equity awards and auditor ratification. Other filings record governance changes, including board membership updates, and identify the company’s registered common stock, Delaware incorporation and reporting framework.
Gain Therapeutics, Inc. (GANX) – Director equity award filing.
On 06/24/2025 director Dr. Dov A. Goldstein filed a Form 4 disclosing the receipt of a stock option for 15,000 common shares at an exercise price of $1.79 per share. The option vests in 12 equal monthly installments beginning 07/24/2025, contingent on the director’s continued service, and carries a 10-year term expiring 06/24/2035.
No common shares were bought or sold; the only reportable event is the option grant. After the transaction, Dr. Goldstein holds 15,000 derivative securities, all in direct ownership form. The filing does not reference any Rule 10b5-1 plan, open-market purchase, or disposition, and there is no indication of additional indirect holdings.
The award appears to be routine director compensation designed to align incentives rather than a signal of a major strategic development. The relatively small size versus GANX’s share count limits any dilution or immediate valuation impact, but it modestly increases insider exposure to the company’s equity performance.
Gain Therapeutics, Inc. (GANX) – Form 4 insider filing
Director Gwen A. Melincoff reported the grant of a derivative security in the form of a stock option for 15,000 common shares on 24 June 2025. The option carries an exercise price of $1.79 per share and will expire on 24 June 2035.
Vesting schedule: the option vests in 12 equal monthly instalments beginning 24 July 2025, contingent on the director’s continued service. No sales, exercises, or other dispositions were reported, and the filing shows direct ownership ("D") of the entire option position.
The filing does not list any non-derivative share transactions, cash compensation, or other equity awards. Because Form 4 must be filed within two business days of a reportable event, this document confirms the timely disclosure of the grant.
For investors, the grant represents routine director compensation and involves a limited potential dilution relative to Gain Therapeutics’ outstanding share count. No immediate cash outlay by the insider was required, and there is no indication of open-market buying or selling.
Gain Therapeutics (GANX) held its Annual Meeting on June 24, 2025, where stockholders approved several key proposals. Most significantly, shareholders approved doubling the company's authorized common stock from 50 million to 100 million shares, with 16.3M votes in favor versus 2.2M against.
The meeting also resulted in the following outcomes:
- All eight director nominees were successfully elected to one-year terms, with Gene Mack, Dov Goldstein, and Gwen Melincoff receiving the highest approval rates
- Ernst & Young AG's appointment as independent auditor was ratified with strong support (18M votes in favor)
- A contingency measure for meeting adjournment was approved with 17.9M supporting votes
The company, an emerging growth company listed on Nasdaq, filed the Certificate of Amendment with Delaware's Secretary of State to formally implement the authorized share increase. This expansion of authorized shares could provide additional flexibility for future capital raising or strategic transactions.